Join our mailing list


    The VRS story – our Triple-A-COAT virology experts



    Virology Research Services Ltd (VRS) is the Triple-A-COAT partner responsible for testing the antiviral activity of our coatings. Earlier this year the company moved into its new premises in Kent, in south-east England.

    We were interested to find out more about the company and the world of antiviral research. VRS co-founder and co-director Dr Michela Mazzon kindly agreed to answer a few of our questions!

    Exterior of VRS new premises in Kent Science Park

    What kind of work do you do at VRS?

    VRS is a Contract Research Organisation (CRO) performing preclinical R&D at the early stages of virus research. This includes testing of antiviral compounds and vaccines, and antiviral materials. We have contracts with academic and industrial customers, including universities, pharmaceutical and biotech companies. VRS works with a wide range of assays and viruses, including many important human pathogens such as HCMV, influenza, Sars-CoV-2, RSV, common cold viruses, and emerging viruses like dengue and Zika viruses.

    As a CRO we prioritize internal R&D efforts, specifically focused on assay development and optimization, as part of our commitment to advancing our bespoke approach.

    Interior of VRS labs
    How did the company start?

    The business started in 2017. At that time I was a post-doctoral scientist, working in antivirals discovery at University College London. My co-founder Chiara Mencarelli and I started to get requests from outside the university to do antiviral testing and other virus research tasks. We realised that there was an opportunity here for a new company to provide virus research services commercially. There is a real need in the market for external CRO support in virus research, as few researchers and companies have access to specialist contained lab facilities, as well as the special knowledge needed.

    First, we worked through UCL Consultants a scheme run by University College London, allowing us to do contract research in the university labs, in our spare time. That really helped us de-risk the business and be sure it was going to work. At the end of 2018 we incorporated VRS and by March 2020 we were able to start working full time in the company. We made our first move off-campus to the science park established at the previous Pfizer site in Kent. At the end of 2022 we moved to our own labs at Kent Science Park.

    Picture of VRS co-founders in their new lab

    How are you finding the new VRS premises in Kent? What advantages does this give you?

    We have now built our own labs at Kent Science Park, where we have our own Containment Level-2 and -3 facilities, so we can perform our full range of operations at one location. A CL-3 lab is a valuable asset that is rarely found within companies (such labs are typically limited to Universities and large research institutions). This specialized facility provides VRS with the necessary safety and security measures to effectively handle higher-risk viruses. Being based outside of London has some advantages for us, while its still easy to travel here from London. Our campus has its own great scientific community, and we also appreciate the fresh air and very nice scenery!

    View of grounds at Kent Science Park

    VRS has a blog on its website where you go into some detail about methods you use for testing antiviral activity. What motivates this open approach?

    We have run this blog on our website since starting VRS. We consider ourselves firstly as scientists working in virus research, and the blog communicates our philosophy as active, troubleshooting scientists. It works at two levels, firstly as a general overview or introduction to virology, but also including advanced technical details for researchers that want to know more. In particular, we want to show to our customers that as scientists we know about the challenges of virus research, and the technical issues or considerations with various assays.

    How is the field of antiviral materials and antiviral testing developing, in general?

    Before 2020, we already knew that a viral pandemic would happen again some time. COVID-19 dramatically increased awareness of the dangers of viruses to people and society in general. There now is a lot more energy in antiviral research, with researchers working on novel, broad spectrum antiviral drugs. There is new interest in the fact that viruses can survive on surfaces for extended periods of time. Viruses are often hard to get rid of. It’s important that solutions are effective, but also safe for humans.

    How is VRS finding participation in the Triple-A-COAT project so far?

    It’s an exciting project, and its very nice that we have four years to really work together. So far in the project meetings I’ve been really impressed at the breadth of expertise of different partners, covering different areas. Not just in developing the antiviral agents but also expertise in nanocellulose and the production and testing of the coatings. It’s an opportunity for VRS to get more into the world of coatings and materials, and a great collaboration for us.

    More from Project news

    • 14/02/2023

      Triple-A-COAT publications

      Our published research will be listed here, with a plain language summary.

      Learn more
    • 21/03/2023

      Triple-A-COAT meeting and 6 month update

      The Triple-A-COAT consortium held its 2nd meeting in Kortrijk, Belgium, home of the KU Leuven Sustainable Materials Laboratory, in the first week of March 2023. Over 20 project team members gathered over 2 days to discuss the progress so far. So far, the project has been running for 6 months. In Kortrijk, Triple-A-COAT partners shared results of their first experiments and tests. Work has started on the …

      Learn more
    • Screenshot of Teams call participants


      EU projects on antimicrobial nanocoatings get together

      Triple-A-COAT is part of a group of research projects funded by the EU Horizon Europe programme to develop new antimicrobial, antiviral and antifungal surface nanocoatings. On May 18th, our sister project SUSAAN organised a zoom call of all the EU-funded project consortia, particularly to discuss potential cooperation on dissemination and communication activities, life cycle assessment (LCA), and sustainability analyses. Around 20 people took part in the joint …

      Learn more
    • 05/04/2023

      Let’s talk about coatings!

      Triple-A-COAT is interested to talk with potential users of its sustainable coatings technology! As part of a “co-creation” process, it is important for researchers to learn about the needs and priorities of users of their technology. The antimicrobial, antifungal and antiviral coatings we are developing in Triple-A-COAT will be first applied in public transport, and a bus manufacturer Van Hool is a partner in the consortium. The …

      Learn more
    Verified by MonsterInsights